Poor
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Multiple dosing, timing, immunogenicity, monitoring, and comparative/market-authorization claims are not supported by the provided prescribing information excerpts and several numeric/statistical statements conflict with label-supported ranges (e.g., dosing for children/adults). Several safety figures (incidence ranges) and efficacy endpoints (adult lipid profile timing, pediatric height outcomes, normal adult height percentages) are unsupported.
Category Scores
Accurate Statements
Dosing for children should be individualized based on growth response and may be divided into equal doses given 3, 6, or 7 days per week.
2.2 Pediatric Dosage: 'Individualize dosage...'; 'Divide the calculated weekly ZOMACTON dosage into equal doses given either 3, 6, or 7 days per week.'
Assess compliance and evaluate other causes of poor growth (e.g., hypothyroidism, under-nutrition, advanced bone age, and antibodies to recombinant human GH) if patients experience failure to increase height velocity, particularly during the first year of treatment.
2.2 Pediatric Dosage: 'Assess compliance and evaluate other causes of poor growth such as hypothyroidism, under-nutrition, advanced bone age and antibodies to recombinant human GH...'
For adults, ZOMACTON is administered daily.
2.3 Adult Dosage: 'Administer the prescribed dose daily.'
Dose titration for adults can be based on clinical response and serum IGF-1 concentrations; dose may be adjusted based on adverse reactions and/or serum IGF-1 above age- and gender-specific normal range.
2.3 Adult Dosage: '...increase... according to individual patient requirements based on the clinical response and serum insulin-like growth factor 1 (IGF-1) concentrations.'; 'Decrease the dose... on the basis of adverse reactions and/or serum IGF-1 concentrations...'
Somatropin may decrease insulin sensitivity; glucose intolerance/diabetes mellitus can occur and glucose should be monitored periodically, especially in patients with risk factors.
5.4 Glucose Intolerance and Diabetes Mellitus: 'Treatment... may decrease insulin sensitivity... New onset type 2 diabetes mellitus has been reported...' and 'Monitor glucose levels periodically...'
Intracranial hypertension symptoms usually occur within the first 8 weeks; fundoscopic exam should be performed routinely before initiating treatment and periodically thereafter; if papilledema is observed, treatment should be stopped; may restart at lower dose after resolution.
5.5 Intracranial Hypertension: multiple statements including timing, fundoscopic exam, stop/restart guidance.
Fluid retention in adults may frequently occur; manifestations include edema, arthralgia, myalgia, and nerve compression syndromes such as carpal tunnel syndrome/paresthesias; usually transient and dose dependent.
5.7 Fluid Retention: complete statement.
Anti-drug antibody incidence is assay-dependent and varies by study; in one trial with another recombinant growth hormone, 1.6% developed specific antibodies within first 6 months.
12.6 Immunogenicity: assay-dependent statement and '1.6% developed specific antibodies...'.
For pediatric GH deficiency patients, the recommended weekly dose range is 0.18 mg/kg/week to 0.3 mg/kg/week (0.026 mg/kg/day to 0.043 mg/kg/day).
2.2 Pediatric Dosage: 'Pediatric GH Deficiency: 0.18 mg/kg/week to 0.3 mg/kg/week (0.026 mg/kg/day to 0.043 mg/kg/day)'.
Unsupported Statements
Zomacton (somatropin) is a recombinant human growth hormone approved by the FDA to treat growth hormone deficiency (GHD) in children and adults.
The provided label excerpts include pediatric use (including growth failure due to inadequate secretion of endogenous growth hormone) but do not provide an adult indication statement in the supplied text.
Clinical trials show Zomacton increases growth velocity in children with GHD by 4-10 cm/year during the first 1-2 years of treatment.
Label excerpt provides mean cumulative increases at 24 weeks and after 12 months for pediatric subgroups, but does not support a 4–10 cm/year during first 1–2 years claim as stated.
In children with GHD, average height gains of 7-12 cm are reported over 3-5 years when somatropin is started early.
No 3–5 year early-start height gain numeric claim is supported by the provided pediatric clinical study excerpt.
In adults, Zomacton improves body composition.
Adult clinical studies in excerpt show changes in lean body mass and fat mass, but the claim is broad and not directly stated as 'improves body composition' in the provided text; numeric details are omitted.
In adults, Zomacton improves lean muscle mass.
Although lean body mass increase is described for another somatropin product in adult studies, the provided label excerpt does not directly state that ZOMACTON (as such) produces that effect.
In adults, Zomacton improves bone density.
Bone density outcomes are not included in the provided adult clinical study excerpt or warnings/precautions excerpts.
Studies report 2-5% increases in lean body mass after 6-12 months in adults.
No percent-based lean body mass increase (2–5%) timing (6–12 months) is supported by the provided excerpt.
About 70-80% of children with GHD reach normal adult height on somatropin.
No such proportion of patients reaching normal adult height is supported by the provided pediatric clinical excerpt.
About 20-30% of children with GHD reach normal adult height without somatropin.
No control/comparator proportion is provided in the supplied pediatric data.
Height velocity improvements in children are often seen within 3-6 months.
The label excerpt reports attainment by 24 weeks (~6 months) but does not support 'often' or 'within 3-6 months' as an interval frequency claim.
Height velocity in children peaks at 12 months.
No statement about a peak at 12 months is supported by the provided pediatric excerpt.
Adults may notice changes in energy, fat distribution, and strength after 1-3 months.
No such patient-experience timing or domains (energy/strength) are supported by the provided labeling excerpts.
Full benefits in adults, such as improved lipid profiles, take 6-12 months.
The adult excerpt provides data through 18 months and mentions normalization of HDL; it does not support a '6-12 months' timing as stated.
Zomacton requires daily subcutaneous injections.
The provided adult dosing excerpt states 'Administer the prescribed dose daily' but does not specify route (subcutaneous) in the supplied text.
The typical dose for children is 0.16-0.24 mg/kg/week.
Label pediatric GH deficiency range shown is 0.18–0.3 mg/kg/week; 0.16–0.24 mg/kg/week is not supported.
The typical dose for adults is 0.2-1 mg/day.
Label adult dosing initiation range in non-weight-based regimen is ~0.15–0.3 mg/day with titration; '0.2-1 mg/day' is not supported by the provided dosing excerpt.
Up to 20-30% of patients show suboptimal response to somatropin.
No such prevalence/range is supported by the supplied prescribing information.
Anti-drug antibodies are rare with somatropin, reported as less than 5%.
Label excerpt does not provide a 'less than 5%' general incidence; it states assay dependence and reports specific trial findings (e.g., 1.6% in one trial with another GH).
Underlying conditions such as celiac disease may contribute to suboptimal response to somatropin.
Celiac disease is not mentioned in the provided pediatric dosage assessment of causes of poor growth.
Doctors monitor growth charts quarterly for children receiving somatropin.
No monitoring frequency for growth charts (quarterly) is provided in the supplied text.
Doctors monitor IGF-1 levels every 6-12 months for adults receiving somatropin.
The provided adult dosing excerpt mentions serum IGF-1 concentrations for dose titration but does not specify IGF-1 monitoring intervals.
Switching brands or stopping somatropin may be done if no benefit after 6-12 months.
The provided label excerpt does not state a 'switch/stop at 6-12 months' rule.
Injection site reactions (pain and redness) affect 20-40% of patients.
No injection site reaction incidence range is provided in the provided labeling excerpts.
Fluid retention, joint pain, or carpal tunnel occur in 10-20% of adults.
The label excerpt describes fluid retention may frequently occur and is usually transient/dose dependent, but does not provide a 10–20% incidence.
Increased intracranial pressure occurs in fewer than 1% of patients.
No incidence threshold ('fewer than 1%') is provided in the supplied text.
Glucose intolerance is a rare risk associated with somatropin.
The label excerpt indicates it may decrease insulin sensitivity and new onset diabetes has been reported, but does not quantify as 'rare.'
Long-term data from trials such as NCGS report no excess cancer risk with proper use of somatropin.
No NCGS trial reference or cancer-risk numeric/absence statement is supported by the provided text.
Zomacton matches the efficacy of Norditropin, Genotropin, and Humatrope in head-to-head studies.
No head-to-head comparative efficacy claims or studies are supported by the provided excerpts.
Zomacton has similar growth outcomes and side effect profiles to Norditropin, Genotropin, and Humatrope.
No comparative side effect profile statements are supported by the provided excerpts.
Zomacton is chosen for its room-temperature stability after reconstitution.
No stability/reconstitution room-temperature duration is provided in the supplied labeling excerpt.
Zomacton is stable at room temperature for 28 days after reconstitution.
No reconstitution stability duration is provided in the supplied labeling excerpt.
Core patents on somatropin expired decades ago.
Patent/legal status statements are not part of the supplied prescribing information excerpts.
Zomacton-specific formulation patents (e.g., US 8,119,602 for stability) expire around 2028-2030.
Patent expiration timelines are not supported by the supplied labeling excerpts.
No active litigation blocks generics yet for Zomacton.
Litigation/genetic market-authorization statements are not supported by the supplied label excerpts.
Biosimilar entry is possible after exclusivity for Zomacton.
Exclusivity/biosimilar entry statements are not supported by the supplied label excerpts.
Contradictions
Low
AI Statement
The typical dose for children is 0.16-0.24 mg/kg/week.
Label Reference
2.2 Pediatric Dosage (Pediatric GH Deficiency): 0.18 mg/kg/week to 0.3 mg/kg/week.
Low
AI Statement
The typical dose for adults is 0.2-1 mg/day.
Label Reference
2.3 Adult Dosage (Non-weight based): initiate ~0.2 mg/day with range 0.15–0.3 mg/day; titration increments approximately 0.1–0.2 mg/day; Weight-based max 0.0125 mg/kg/day.
Low
AI Statement
Zomacton requires daily subcutaneous injections.
Label Reference
2.3 Adult Dosage and 2.2 Pediatric Dosage provided excerpts specify 'daily' and dosing frequency but do not state 'subcutaneous' route in the supplied text.
Important Omissions
Dose selection criteria for adults: reevaluation before continuation for those treated in childhood with closed epiphyses; specific guidance on geriatric lower starting dose and smaller increments; possible higher doses for estrogen-replete women/patients on oral estrogen; weight-based regimen not recommended for obese patients.
Importance:
Moderate
Key pediatric dosing individualization guidance beyond GH deficiency range (e.g., Turner syndrome, idiopathic short stature, SHOX deficiency, SGA dosing and special considerations) and titration/gradual reduction guidance after catch-up growth.
Importance:
Moderate
For immunogenicity and suboptimal response, label-supported causes include antibodies to recombinant human GH; label does not support a blanket numeric 'anti-drug antibodies <5%'.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Numerous dosing and incidence/timing claims are unsupported or inconsistent with the provided label excerpts, which could lead to inaccurate expectations about dosing amounts and risks (e.g., adult dose range, incidence percentages for adverse events, and monitoring intervals).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Large number of quantitative efficacy/safety/market/patent and specific dosing/monitoring claims are not supported by the provided prescribing information excerpts, and some dosing ranges are inconsistent with label guidance.
Suggested Improvement
Limit statements to what is explicitly supported in the provided label excerpts (indications, pediatric and adult dosing regimens with correct ranges and titration rules, and label-described adverse reaction topics without unsupported incidence/timing or external comparative/patent/legal claims). Replace speculative numeric claims with label-supported values and omit non-label legal/market authorization statements.